Ribociclib
Novartis
['bcsm', 'breast']
. covers study presented at #asco23 (lba500) that a drug used in the early stage of hr+/her2- breast cancer significantly reduced the risk of the cancer returning after treatment: #bcsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.